Search Results

LumiThera Inc. announced an update on the regulatory status of the Valeda® Light Delivery System.

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda ® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD).

LumiThera Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI) of up to $2.3M in funding over two years.

LumiThera Inc. today announced the 24-month data from its LIGHTSITE III, multi-center clinical trial which demonstrated sustained vision improvement in dry Age-Related Macular Degeneration (AMD) subjects treated with the Valeda ® Light Delivery System.

LumiThera Inc., a commercial stage medical device company offering photobiomodulation treatment for ocular damage and disease, announced the purchase of MacuLogix assets by its wholly owned subsidiary.

LumiThera Inc. is proud to announce that the AdaptDx Pro® has been recognized as one of Fast Company’s 2022 Innovation and Design Award honorees.

LumiThera Inc., a commercial stage medical device company offering photobiomodulation treatment for ocular damage and disease, announced the completion of a debt financing with Leste Clearway and Serengeti Asset Management.

LumiThera Inc today announced the completion of its acquisition of Diopsys, Inc., a leader in modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders.

LumiThera Inc announced detailed findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular Age-Related Macular Degeneration subjects treated with Photobiomodulation using the Valeda® Light Delivery System.

LumiThera Inc. announced positive findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular Age-Related Macular Degeneration subjects treated with the Valeda® Light Delivery System.